Avalo Therapeutics AVTX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's common stock, shares authorized (in shares)?
- Avalo Therapeutics (AVTX) reported common stock, shares authorized (in shares) of $200M in Q1 2026.
- How has Avalo Therapeutics's common stock, shares authorized (in shares) changed year-over-year?
- Avalo Therapeutics's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $200M to $200M.
- What is the long-term trend for Avalo Therapeutics's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Avalo Therapeutics's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.